Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články
PubMed
30504389
DOI
10.21873/anticanres.13048
PII: 38/12/6771
Knihovny.cz E-zdroje
- Klíčová slova
- Nivolumab, biomarker, non-small cell lung cancer, overall survival, progression-free survival,
- MeSH
- analýza přežití MeSH
- chronická nemoc MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory plic komplikace diagnóza farmakoterapie mortalita MeSH
- nemalobuněčný karcinom plic komplikace diagnóza farmakoterapie mortalita MeSH
- nivolumab terapeutické užití MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- zánět komplikace diagnóza mortalita MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- nivolumab MeSH
AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. CONCLUSION: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.
Department of Oncology Charles University 1st Faculty of Medicine Prague Prague Czech Republic
Department of Oncology Palacky University Faculty of Medicine and Dentistry Olomouc Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
